Redesigner drugs

Nature Biotechnology

Volumn 22, Issue 8, 2004, Pages 953-957

  Dove, Alan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PRODUCT DEVELOPMENT; RISK ASSESSMENT;

DRUG DEVELOPMENT; PROFITABILITY;

DRUG PRODUCTS;

ABCIXIMAB; AD 452; ALPHA 1 ANTITRYPSIN; AMX 174; ASCOMYCIN; ATI 2042; ATI 7506; BLOOD CLOTTING FACTOR 9; CISAPRIDE; DEOXYRIBONUCLEASE; ENOXAPARIN; ERYTHROPOIETIN; ESZOPICLONE; ETANERCEPT; FEXOFENADINE; FOLLITROPIN; GABAPENTIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; IMIGLUCERASE; INFLIXIMAB; LEVALBUTEROL; M 118; METHYLPHENIDATE; PALIVIZUMAB; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; SALBUTAMOL; TERFENADINE; TRASTUZUMAB; TRU 015; TRX 1; TRX 4; UNINDEXED DRUG; WARFARIN; XP 13513;

BIOTECHNOLOGY; DRUG DESIGN; DRUG EFFECT; DRUG MARKETING; DRUG METABOLISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; HEART DISEASE; HUMAN; INVESTMENT; PATENT; PRIORITY JOURNAL; PROFIT; REVIEW; SIDE EFFECT; STRUCTURE ANALYSIS;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG INDUSTRY; DRUG THERAPY; EUROPEAN UNION; OWNERSHIP; PATENTS; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 3543016745     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0804-953     Document Type: Review

References (5)

1. FDA's policy statement for the development of new stereoisomeric drugs. US Food and Drug Administration Center for Drug Evaluation and Research, 1 May 1992. http://www.fda.gov/cder/guidance/stereo.htm
2. Cundy, K.C. et al. XP13512, a novel gabapentin prodrug: 1. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J. Pharmacol. Exp. Ther., published online 24 June 2004.
3. Umana, P. et al. Engineered glycoforms of an antineuroblastoma IgG with optimized antibody-dependent cellular cytotoxicity activity. Nat. Biotechnol. 17, 176-180 (1999).
4. Preventable drug interactions: A focus on drug interactions. US Food and Drug Administration Center for Drug Evaluation and Research, 31 July 2002. http://www.fda.gov/cder/drug/drugReactions/default.htm-ADRs: %20Prevalence%20and%20Incidence.
5. Sundaram, M. et al. Rational design of low molecular weight heparins with improved in vivo activity. Proc. Natl. Acad. Sci. USA 100, 651-656 (2003).